Both remain the most effective weight-loss medications available
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
This can further reduce your actual out-of-pocket cost beyond the already low $149/month pricing, making direct-pay compounded therapy even more affordable than insurance-covered alternatives for many patients
More than half of the participants on the two higher doses lost at least 20% of their body weight
You want someone who treats this as a medical procedure, not just a spa service
Regarding survival times, the mean survival time was 474 days, with a median of 381 days , and a range from 152 to 1,989 days